Published in Am J Kidney Dis on February 01, 2007
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol (2010) 1.93
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension (2009) 1.88
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 1.46
Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol (2010) 1.44
Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol (2009) 1.37
Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27
Cardiotoxicity and oncological treatments. Dtsch Arztebl Int (2014) 1.23
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol (2013) 1.21
Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J Clin Endocrinol Metab (2009) 1.16
Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet Gynecol (2010) 1.14
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep (2012) 1.10
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A (2013) 1.09
Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer (2009) 1.09
Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant (2011) 1.09
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist (2011) 1.08
A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One (2010) 1.08
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol (2010) 1.08
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol (2009) 1.03
Mechanisms and potential therapies for preeclampsia. Curr Hypertens Rep (2011) 1.02
Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis (2013) 1.02
Management of antiangiogenic therapy-induced hypertension. Hypertension (2012) 1.02
Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res (2011) 1.02
Molecular mechanisms of diabetic vascular complications. J Diabetes Investig (2010) 1.01
Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med (2012) 0.99
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97
Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair (2012) 0.96
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist (2010) 0.96
Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) (2013) 0.96
Chemotherapy-associated renal dysfunction. Nat Rev Nephrol (2009) 0.95
Medical management of brain tumors and the sequelae of treatment. Neuro Oncol (2014) 0.94
Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension (2012) 0.93
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond) (2012) 0.93
Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets. Chem Biol (2009) 0.92
Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am J Physiol Renal Physiol (2008) 0.92
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia (2008) 0.92
Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One (2013) 0.91
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol (2009) 0.91
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol (2010) 0.89
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer (2012) 0.88
VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol (2012) 0.87
The glomerular filtration barrier: components and crosstalk. Int J Nephrol (2012) 0.87
Model-based treatment optimization of a novel VEGFR inhibitor. Br J Clin Pharmacol (2012) 0.86
Role of the podocyte in proteinuria. Pediatr Nephrol (2010) 0.86
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer (2012) 0.86
Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study. Atherosclerosis (2014) 0.86
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res (2015) 0.85
Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol (2014) 0.85
Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One (2014) 0.85
Bevacizumab in the treatment of ovarian cancer. Biologics (2011) 0.85
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol (2014) 0.85
Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol (2012) 0.84
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) (2010) 0.84
Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract (2011) 0.84
Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol (2013) 0.84
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol (2012) 0.84
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol (2014) 0.83
Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol (2015) 0.83
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One (2014) 0.83
Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension (2009) 0.83
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol (2014) 0.83
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. Am J Physiol Renal Physiol (2015) 0.83
New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther (2014) 0.83
Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget (2016) 0.83
Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol (2010) 0.82
Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol (2014) 0.82
Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol (2010) 0.82
Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol (2013) 0.81
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol (2013) 0.81
Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data. Phys Med Biol (2012) 0.81
Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv (2011) 0.81
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer (2014) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist (2015) 0.80
The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol (2016) 0.80
Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN. Eye (Lond) (2013) 0.80
ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy. J Am Soc Nephrol (2015) 0.80
Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. Oncol Lett (2016) 0.80
Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol (2008) 0.79
Potent inhibition of VEGFR-2 activation by tight binding of green tea epigallocatechin gallate and apple procyanidins to VEGF: relevance to angiogenesis. Mol Nutr Food Res (2015) 0.79
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? World J Gastroenterol (2013) 0.78
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78
SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice. PLoS One (2014) 0.78
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Targeted therapies in epithelial ovarian cancer. Cancers (Basel) (2010) 0.77
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.54
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int (2011) 5.70
Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care (2007) 3.19
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med (2014) 2.93
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol (2009) 2.87
Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis (2008) 2.85
Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg (2010) 2.61
Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int (2009) 2.53
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol (2009) 2.43
Acute kidney injury in cirrhosis. Hepatology (2008) 2.43
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis (2013) 2.42
Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med (2011) 2.41
Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis (2010) 2.35
Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA (2006) 2.22
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Ascertainment and epidemiology of acute kidney injury varies with definition interpretation. Clin J Am Soc Nephrol (2008) 2.18
Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant (2008) 2.14
Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol (2011) 2.11
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol (2012) 2.00
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Living kidney donors requiring transplantation: focus on African Americans. Transplantation (2007) 1.92
New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med (2012) 1.91
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol (2012) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery. Kidney Int (2011) 1.88
The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88
Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol (2008) 1.85
Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation (2008) 1.83
Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol (2008) 1.83
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol (2009) 1.82
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans. Kidney Int (2010) 1.81
Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant (2008) 1.74
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis (2007) 1.66
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol (2010) 1.64
Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int (2012) 1.64
The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol (2010) 1.63
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Acute dialysis risk in living kidney donors. Nephrol Dial Transplant (2012) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Renal impairment predicts long-term mortality risk after acute myocardial infarction. J Am Soc Nephrol (2007) 1.57
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant (2007) 1.55
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Urinary biomarkers for acute kidney injury: perspectives on translation. Clin J Am Soc Nephrol (2008) 1.51
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol (2010) 1.50
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (2010) 1.48
Contribution of acute kidney injury toward morbidity and mortality in burns: a contemporary analysis. Am J Kidney Dis (2007) 1.48
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin J Am Soc Nephrol (2011) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant (2005) 1.41
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol (2008) 1.39
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol (2005) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med (2012) 1.34
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer (2009) 1.34
Secular trends in acute dialysis after elective major surgery--1995 to 2009. CMAJ (2012) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Association of postoperative proteinuria with AKI after cardiac surgery among patients at high risk. Clin J Am Soc Nephrol (2012) 1.32
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology (2010) 1.31
Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J Kidney Dis (2004) 1.31
The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS (2008) 1.30
Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep (2013) 1.24
Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol (2010) 1.23
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. Clin J Am Soc Nephrol (2012) 1.20
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol (2008) 1.20
Characterization of acute liver failure and development of a continuous risk of death staging system in children. J Hepatol (2005) 1.20
The association of albumin/creatinine ratio with postoperative AKI in children undergoing cardiac surgery. Clin J Am Soc Nephrol (2012) 1.20
Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail (2013) 1.19
Presurgical serum cystatin C and risk of acute kidney injury after cardiac surgery. Am J Kidney Dis (2011) 1.17
Predicting acute kidney injury after cardiac surgery: a systematic review. Ann Thorac Surg (2012) 1.17
Evaluating the ROC performance of markers for future events. Lifetime Data Anal (2007) 1.16
Health insurance status of US living kidney donors. Clin J Am Soc Nephrol (2010) 1.16
Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis. Am J Kidney Dis (2005) 1.16
Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol (2010) 1.15
Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. Clin J Am Soc Nephrol (2012) 1.13
Acetaminophen toxicity: suicidal vs. accidental. Crit Care (2002) 1.13
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther (2008) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13